Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia  .

CONCLUSION: Our data suggest that a drug-drug interaction between candesartan cilexetil and TC therapy is probable. Unlike with other ARBs, the possible increased risk for development of severe neutropenia should be taken into account when prescribing candesartan cilexetil in combination with TC therapy. . PMID: 29792394 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29792394?dopt=Abstract

Source: International Journal of Clinical Pharmacology and Therapeutics - May 27, 2018 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia .

Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia  .